Guangzhou Baiyunshan Pharmaceutical Holdings (00874) subsidiary Mingxing Pharmaceutical received the "Drug Production License" approved and issued by the Guangdong Provincial Food and Drug Administration.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its wholly-owned subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Mingxing Pharmaceutical Co., Ltd. (hereinafter referred to as "Mingxing Pharmaceutical"), recently received approval from the Guangdong Provincial Drug Administration to issue a "Drug Production License." This allows Mingxing Pharmaceutical to add new production workshops, production lines, and production scope, and it has passed the inspection of compliance with drug production quality management standards. The addition of new production workshops, production lines, and production scope, as well as passing the inspection of compliance with drug production quality management standards, will help optimize production capacity, enhance the level of intelligence, digitization, and greenification, continue to maintain stable production capacity, and meet market demand. The acquisition of the "Drug Production License" in this instance will have no significant impact on the company's current performance.